TriangleNCT00410761 · OUTCOME
Objective Response Rate (ORR)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- RECIST assessments performed at screening (within 3 weeks before randomisation), then every 12 weeks. For patients with objective response of CR or PR, an additional confirmatory scan was performed ≥4 weeks following the date of first response.
What was measured
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria. The categories for best objective response are CR, PR, stable disease (SD)\>= 12 weeks, progressive disease (PD) or NE.
Groups in this outcome
Vandetanib 300 mg
Vandetanib (300 mg daily)
Placebo
Placebo daily
| Group | Source count |
|---|---|
| Vandetanib 300 mg | 231 |
| Placebo | 100 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Vandetanib 300 mg | 104 | Not reported | Not reported | Not reported | Not reported |
| Placebo | 13 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 104
- group Id
- OG001
- value
- 13
- denoms
- counts
- group Id
- OG000
- value
- 231
- group Id
- OG001
- value
- 100
- units
- Participants
- description
- The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria. The categories for best objective response are CR, PR, stable disease (SD)\>= 12 weeks, progressive disease (PD) or NE.
- groups
- description
- Vandetanib (300 mg daily)
- id
- OG000
- title
- Vandetanib 300 mg
- description
- Placebo daily
- id
- OG001
- title
- Placebo
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- RECIST assessments performed at screening (within 3 weeks before randomisation), then every 12 weeks. For patients with objective response of CR or PR, an additional confirmatory scan was performed ≥4 weeks following the date of first response.
- title
- Objective Response Rate (ORR)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice